Skip to content
OpenCapital
Get started
Phathom Pharmaceuticals, Inc. logo

Phathom Pharmaceuticals, Inc. (PHAT) Q1 2026 Earnings

PHAT·Reported April 30, 2026·Before market open

Phathom Pharmaceuticals, Inc. reported Q1 2026 revenue of $58.3M (+104.4% YoY), beat analyst consensus of $55.9M by $2.4M. Diluted EPS came in at $-0.37 (+65.4% YoY), missed the $-0.27 consensus by $0.10.

Revenue
$58.3Mbeat by $2.4M
Consensus: $55.9M
Diluted EPS
$-0.37missed by $0.10
Consensus: $-0.27
SEC

SEC Filings

Earnings release8-K · 0001193125-26-193945
Quarterly report10-Q · 0001193125-26-193946

Financial Snapshot

Trailing eight quarters through Q1 2026

View all metrics

Q1 2026 Earnings FAQ

Common questions about Phathom Pharmaceuticals, Inc.'s Q1 2026 earnings report.

Phathom Pharmaceuticals, Inc. (PHAT) reported Q1 2026 earnings on April 30, 2026 before market open.

Phathom Pharmaceuticals, Inc. reported revenue of $58.3M and diluted EPS of $-0.37 for Q1 2026.

Revenue beat the consensus estimate of $55.9M by $2.4M. EPS missed the consensus estimate of $-0.27 by $0.10.

Compared to the same quarter a year prior, revenue grew 104.4% from $28.5M a year earlier and diluted EPS grew 65.4% from $-1.07.

You can read the 8-K earnings release (0001193125-26-193945) and the 10-Q periodic report (0001193125-26-193946) directly on SEC EDGAR. The filing index links above go to sec.gov.